12.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Precedente Chiudi:
$12.85
Aprire:
$12.74
Volume 24 ore:
924.64K
Relative Volume:
0.71
Capitalizzazione di mercato:
$745.44M
Reddito:
-
Utile/perdita netta:
$-130.41M
Rapporto P/E:
-5.3884
EPS:
-2.24
Flusso di cassa netto:
$-67.76M
1 W Prestazione:
-2.03%
1M Prestazione:
+55.94%
6M Prestazione:
+142.86%
1 anno Prestazione:
+35.62%
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Nome
Monte Rosa Therapeutics Inc
Settore
Industria
Telefono
617-949-2643
Indirizzo
321 HARRISON AVENUE, BOSTON
Confronta GLUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
GLUE
Monte Rosa Therapeutics Inc
|
12.07 | 793.61M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Iniziato | UBS | Buy |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
Mostra tutto
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Monte Rosa Therapeutics (NASDAQ: GLUE) sets investor chats; 30-day webcasts available - Stock Titan
Is it time to cut losses on Monte Rosa Therapeutics Inc.Market Volume Report & Stock Timing and Entry Methods - newser.com
What to do if you’re stuck in Monte Rosa Therapeutics Inc.Dividend Hike & Low Risk Investment Opportunities - newser.com
Is Monte Rosa Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Decliners & Accurate Technical Buy Alerts - newser.com
Why Monte Rosa Therapeutics Inc. stock could benefit from AI revolutionWeekly Stock Report & High Return Trade Guides - newser.com
Chart based exit strategy for Monte Rosa Therapeutics Inc.2025 Top Gainers & Community Verified Trade Signals - newser.com
Forecasting Monte Rosa Therapeutics Inc. price range with options dataMarket Movers & Safe Entry Trade Reports - newser.com
Cwm LLC Raises Holdings in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics, Inc. (GLUE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Monte Rosa Therapeutics, Inc. (GLUE) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Monte Rosa Therapeutics (NASDAQ:GLUE) Given Sell (D+) Rating at Weiss Ratings - MarketBeat
Monte Rosa Therapeutics Hits New 52-Week High of $13.10 - Markets Mojo
Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Custom watchlist performance reports with Monte Rosa Therapeutics Inc.Bull Run & Technical Entry and Exit Alerts - newser.com
Visual trend scoring systems applied to Monte Rosa Therapeutics Inc.Weekly Market Summary & Expert-Curated Trade Recommendations - newser.com
Why Monte Rosa Therapeutics Inc. stock is popular among millennialsJuly 2025 Outlook & Technical Pattern Alert System - newser.com
Monte Rosa Therapeutics Advances MRT-2359 in MYC-Driven Cancer Study - MSN
Monte Rosa Therapeutics Hits New 52-Week High of $12.97 - Markets Mojo
Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study - MSN
What analysts say about Monte Rosa Therapeutics Inc stockDividend Reinvestment Plans & Small Investment Growth Tips - earlytimes.in
How Regulatory Changes Could Impact ICDS Limiteds BusinessRelative Strength Index (RSI) & Learn to Trade Without Fear of Loss - earlytimes.in
Working capital per share of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Published on: 2025-10-30 01:39:11 - newser.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - Yahoo Finance
Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 1-Year HighStill a Buy? - MarketBeat
Why Monte Rosa Therapeutics Inc. stock is trending among retail tradersJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - fcp.pa.gov.br
Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):